Status:
COMPLETED
Frequency of SOD1 and C9orf72 Gene Mutations in French ALS
Lead Sponsor:
University Hospital, Tours
Collaborating Sponsors:
Biogen
Conditions:
Amyotrophic Lateral Sclerosis
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of the study is to determine the frequency of mutations in the C9orf72 and SOD1 genes in the incident population of ALS patients followed in the FILSLAN centres
Detailed Description
After obtaining free and informed consent for genetic characteristic tests, a blood sample will be taken during hospitalisation for diagnostic confirmation or during the quarterly multidisciplinary co...
Eligibility Criteria
Inclusion
- Adult aged ≥ 18 years old
- ALS defined, probable or likely based on neurophysiological data according to Airlie House criteria (Brooks, 2000)
- Sporadic ALS or familial ALS defined by the existence of a case of ALS or FTD among first or second degree relatives of the patient included (Byrne et al, 2011).
- Participant affiliated to a social security scheme
- Free, informed and signed consent for the examination of the genetic characteristics of the participant
Exclusion
- All conditions mimicking ALS including motor neuropathies with multiple conduction blocks and all cases of ALS that do not meet the criteria of the Airlie House classification.
- Patients who are cognitively incapable of signing the consent to participate in this study.
Key Trial Info
Start Date :
April 30 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 15 2023
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04819555
Start Date
April 30 2021
End Date
May 15 2023
Last Update
November 30 2023
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Angers
Angers, France, 49000
2
CHU Bordeaux
Bordeaux, France, 33000
3
CHU de Brest
Brest, France, 29200
4
CHU Lyon
Bron, France, 69677